.Attributes Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the empirical SCRUM-Japan GOZILA research study, after a median follow-up of 11 months, patients with metastatic stomach lumps that obtained biomarker-matched therapies based upon flowing lump DNA profiling showed a more significant professional benefit than those acquiring unparalleled treatment.